{
  "docId": "019de070-a5cb-72a4-ac7d-0f26e10cd805",
  "docSlug": "05d98084f9bd31c78a17b84718191aae",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 39 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 36,
  "pageCount": 39,
  "prevPage": 35,
  "nextPage": 37,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide uses a three-column layout to summarize key business pillars.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-a5cb-72a4-ac7d-0f26e10cd805/36",
  "deckHref": "/decks/019de070-a5cb-72a4-ac7d-0f26e10cd805",
  "deckJsonHref": "/decks/019de070-a5cb-72a4-ac7d-0f26e10cd805.json",
  "deckAnchorHref": "/decks/019de070-a5cb-72a4-ac7d-0f26e10cd805#slide-36",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "list",
      "text": "Global presence: Balanced specialty and primary-care franchises; Leading emerging markets presence with R&D base",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "48740bc9-a968-4371-bce9-b406afd1ddf4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.68,
        "y": 0.25
      },
      "kind": "list",
      "text": "Improving financials: Eight blockbuster medicines; Returned to durable revenue and earnings growth; Focus on operating leverage and cash flow",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae4c3e0b-40ac-48af-96fd-0bdede15e4bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.36,
        "y": 0.25
      },
      "kind": "list",
      "text": "Strong pipeline: 22 Phase III medicines and significant lifecycle projects; Advancing early- and mid-stage pipeline",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e943a6fc-2237-4d35-b7db-5090dc68919a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.94,
        "x": 0.03,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "Innovative medicines in Oncology and BioPharmaceuticals; Experienced and proven team",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "73dd8b4f-32eb-48ec-ac2c-9204426b7fd9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1. In FY 2020, speciality-care medicines (Oncology, Brilinta, Lokelma, roxadustat and Fasenra) comprised 53% of total revenue 2. Cardiovascular, Renal & Metabolism and Respiratory & Immunology.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0187fe4-21ac-4085-80dc-ed75c65a3096",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.35,
        "x": 0.03,
        "y": 0.11
      },
      "kind": "title",
      "text": "Pipeline-driven transformation",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3634db43-9cf2-443a-a334-d762f8bfe0d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.35,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "AstraZeneca in summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f450f135-bed4-4f3d-b07e-91580a66f8e1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "88aa1c84-b18f-4506-abdc-9950ff425ace",
      "evidence": "The slide presents a summary of the company's transformation, with a list of bullet points highlighting key achievements.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 39,
      "from": 19,
      "beatId": "0e550b23-20ef-4625-a839-81a772e4622a",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The document concludes with a call to action and next steps",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}